SABCS 2022: Trastuzumab Deruxtecan Linked to High Overall Response as Neoadjuvant Therapy
Treatment demonstrated promising clinical activity, with and without endocrine therapy, in patients with breast cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.